Intellipharmaceutics International Inc. (IPCIF)
USD 0.15
(N/A%)
USD 0.15
(N/A%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 65.72 Thousand USD | 134.46% |
| 2022 | -190.72 Thousand USD | -119.65% |
| 2021 | 970.58 Thousand USD | -29.07% |
| 2020 | 1.36 Million USD | -13.82% |
| 2019 | 1.58 Million USD | -66.92% |
| 2018 | 4.8 Million USD | 181.09% |
| 2017 | -5.91 Million USD | -87.71% |
| 2016 | -3.15 Million USD | -520.78% |
| 2015 | 749.49 Thousand USD | 121.12% |
| 2014 | -3.54 Million USD | 39.7% |
| 2013 | -5.88 Million USD | -27.28% |
| 2012 | -4.62 Million USD | -50.42% |
| 2011 | -3.07 Million USD | 0.0% |
| 2009 | - USD | 0.0% |
| 2008 | - USD | 0.0% |
| 2007 | - USD | 0.0% |
| 2006 | - USD | 0.0% |
| 2005 | - USD | 0.0% |
| 2004 | - USD | 0.0% |
| 2003 | - USD | -100.0% |
| 2002 | 1000.03 USD | -99.53% |
| 2001 | 213.98 Thousand USD | -28.71% |
| 2000 | 300.17 Thousand USD | 50.33% |
| 1999 | 199.67 Thousand USD | 184.14% |
| 1998 | 70.27 Thousand USD | -5.31% |
| 1997 | 74.21 Thousand USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 274.84 Thousand USD | 825.96% |
| 2024 Q3 | -805 Thousand USD | -280.35% |
| 2024 Q2 | 446.36 Thousand USD | 62.41% |
| 2023 FY | 65.72 Thousand USD | 134.46% |
| 2023 Q3 | 19.06 Thousand USD | -39.83% |
| 2023 Q4 | 29.68 Thousand USD | 55.66% |
| 2023 Q1 | 83.41 Thousand USD | 229.85% |
| 2023 Q2 | 31.69 Thousand USD | -62.01% |
| 2022 FY | -190.72 Thousand USD | -119.65% |
| 2022 Q1 | -65.84 Thousand USD | -121.99% |
| 2022 Q2 | 93.42 Thousand USD | 241.9% |
| 2022 Q3 | -64.41 Thousand USD | -168.95% |
| 2022 Q4 | -64.23 Thousand USD | 0.27% |
| 2021 Q2 | 395.74 Thousand USD | 4.82% |
| 2021 Q4 | 299.44 Thousand USD | -8.92% |
| 2021 Q1 | 377.55 Thousand USD | 101.15% |
| 2021 FY | 970.58 Thousand USD | -29.07% |
| 2021 Q3 | 328.78 Thousand USD | -16.92% |
| 2020 Q2 | 1.21 Million USD | 291.19% |
| 2020 Q3 | 1.68 Million USD | 39.14% |
| 2020 Q4 | -32.78 Million USD | -2040.23% |
| 2020 FY | 1.36 Million USD | -13.82% |
| 2020 Q1 | 310.46 Thousand USD | -16.99% |
| 2019 FY | 1.58 Million USD | -66.92% |
| 2019 Q4 | 373.99 Thousand USD | 1.56% |
| 2019 Q1 | -701.05 Million USD | -73031.0% |
| 2019 Q3 | 368.25 Thousand USD | -27.95% |
| 2019 Q2 | 511.09 Thousand USD | 100.07% |
| 2018 FY | 4.8 Million USD | 181.09% |
| 2018 Q1 | -795.82 Thousand USD | -239.84% |
| 2018 Q3 | 813.68 Thousand USD | -54.55% |
| 2018 Q2 | 1.79 Million USD | 324.94% |
| 2018 Q4 | 961.25 Thousand USD | 18.14% |
| 2017 Q1 | -1.24 Million USD | 80.54% |
| 2017 Q2 | 556.04 Thousand USD | 144.64% |
| 2017 Q3 | 554.92 Thousand USD | -0.2% |
| 2017 Q4 | 569.09 Thousand USD | 2.55% |
| 2017 FY | -5.91 Million USD | -87.71% |
| 2016 FY | -3.15 Million USD | -520.78% |
| 2016 Q1 | 121.36 Thousand USD | 101.87% |
| 2016 Q4 | -6.4 Million USD | -666.02% |
| 2016 Q2 | -325.5 Thousand USD | -368.21% |
| 2016 Q3 | -835.8 Thousand USD | -156.77% |
| 2015 Q4 | -6.48 Million USD | -944.25% |
| 2015 FY | 749.49 Thousand USD | 121.12% |
| 2015 Q3 | -620.84 Thousand USD | 67.04% |
| 2015 Q2 | -1.88 Million USD | -156.68% |
| 2015 Q1 | 3.32 Million USD | 1322.03% |
| 2014 FY | -3.54 Million USD | 39.7% |
| 2014 Q1 | -1.33 Million USD | 26.71% |
| 2014 Q2 | -934.06 Thousand USD | 30.18% |
| 2014 Q3 | -1 Million USD | -7.59% |
| 2014 Q4 | -271.97 Thousand USD | 72.94% |
| 2013 Q2 | -1.09 Million USD | 42.08% |
| 2013 Q4 | -1.82 Million USD | -42.67% |
| 2013 Q3 | -1.27 Million USD | -16.48% |
| 2013 Q1 | -1.89 Million USD | -49.98% |
| 2013 FY | -5.88 Million USD | -27.28% |
| 2012 Q4 | -1.26 Million USD | -71.92% |
| 2012 Q1 | -1.18 Million USD | -1.79% |
| 2012 FY | -4.62 Million USD | -50.42% |
| 2012 Q3 | -735.47 Thousand USD | 48.73% |
| 2012 Q2 | -1.43 Million USD | -20.59% |
| 2011 Q4 | -1.16 Million USD | 21.21% |
| 2011 Q2 | 274.85 Thousand USD | 139.43% |
| 2011 Q1 | -697.06 Thousand USD | 0.0% |
| 2011 FY | -3.07 Million USD | 0.0% |
| 2011 Q3 | -1.48 Million USD | -639.6% |
| 2010 Q3 | - USD | 0.0% |
| 2010 Q2 | - USD | 100.0% |
| 2010 Q1 | -28.35 Thousand USD | 0.0% |
| 2009 FY | - USD | 0.0% |
| 2009 Q4 | - USD | 0.0% |
| 2009 Q3 | - USD | 0.0% |
| 2009 Q2 | - USD | 100.0% |
| 2009 Q1 | -2.83 Million USD | 0.0% |
| 2008 FY | - USD | 0.0% |
| 2008 Q4 | - USD | 0.0% |
| 2008 Q1 | - USD | 0.0% |
| 2008 Q3 | - USD | 0.0% |
| 2008 Q2 | - USD | 0.0% |
| 2007 Q3 | - USD | 0.0% |
| 2007 Q1 | - USD | 0.0% |
| 2007 FY | - USD | 0.0% |
| 2007 Q4 | - USD | 0.0% |
| 2007 Q2 | - USD | 0.0% |
| 2006 Q1 | - USD | 0.0% |
| 2006 Q4 | - USD | 0.0% |
| 2006 Q3 | - USD | 0.0% |
| 2006 Q2 | - USD | 0.0% |
| 2006 FY | - USD | 0.0% |
| 2005 Q1 | - USD | 0.0% |
| 2005 Q3 | - USD | 0.0% |
| 2005 FY | - USD | 0.0% |
| 2005 Q2 | - USD | 0.0% |
| 2005 Q4 | - USD | 0.0% |
| 2004 Q4 | - USD | 0.0% |
| 2004 Q1 | - USD | 0.0% |
| 2004 Q2 | - USD | 0.0% |
| 2004 Q3 | - USD | 0.0% |
| 2004 FY | - USD | 0.0% |
| 2003 Q2 | - USD | 0.0% |
| 2003 Q1 | - USD | 100.0% |
| 2003 Q4 | - USD | 0.0% |
| 2003 FY | - USD | -100.0% |
| 2003 Q3 | - USD | 0.0% |
| 2002 Q1 | 56 Thousand USD | 14.02% |
| 2002 FY | 1000.03 USD | -99.53% |
| 2002 Q3 | 58 Thousand USD | 3.57% |
| 2002 Q4 | -0.18 USD | -100.0% |
| 2002 Q2 | 55.99 Thousand USD | -0.0% |
| 2001 FY | 213.98 Thousand USD | -28.71% |
| 2001 Q4 | 49.11 Thousand USD | -39.31% |
| 2001 Q3 | 80.93 Thousand USD | 92.96% |
| 2001 Q2 | 41.94 Thousand USD | -4.6% |
| 2001 Q1 | 43.96 Thousand USD | -56.23% |
| 2000 Q1 | 100.1 Thousand USD | -26.61% |
| 2000 Q3 | 99.86 Thousand USD | 0.15% |
| 2000 FY | 300.17 Thousand USD | 50.33% |
| 2000 Q4 | 100.44 Thousand USD | 0.58% |
| 2000 Q2 | 99.72 Thousand USD | -0.39% |
| 1999 Q1 | 70.26 Thousand USD | 4184.71% |
| 1999 Q2 | 68.65 Thousand USD | -2.29% |
| 1999 Q4 | 136.4 Thousand USD | 115.57% |
| 1999 Q3 | 63.27 Thousand USD | -7.83% |
| 1999 FY | 199.67 Thousand USD | 184.14% |
| 1998 Q2 | 72.55 Thousand USD | -0.7% |
| 1998 Q3 | 71.99 Thousand USD | -0.78% |
| 1998 Q1 | 73.06 Thousand USD | 0.0% |
| 1998 FY | 70.27 Thousand USD | -5.31% |
| 1998 Q4 | -1720.17 USD | -102.39% |
| 1997 FY | 74.21 Thousand USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Arch Therapeutics, Inc. | -2439.00 USD | 2794.875% |
| Evofem Biosciences, Inc. | 11.7 Million USD | 99.439% |
| Nascent Biotech, Inc. | -319.5 Thousand USD | 120.572% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| Santhera Pharmaceuticals Holding AG | 119.1 Million USD | 99.945% |
| Qrons Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | -25.79 Million USD | 100.255% |
| ProtoKinetix, Incorporated | -48.25 Thousand USD | 236.198% |
| Skye Bioscience, Inc. | -124.25 Thousand USD | 152.899% |
| Eiger BioPharmaceuticals, Inc. | 14.99 Million USD | 99.562% |
| Nanobac Pharmaceuticals, Incorporated | 3102.00 USD | -2018.891% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| SQZ Biotechnologies Company | 9.79 Million USD | 99.329% |
| Propanc Biopharma, Inc. | -34.15 Thousand USD | 292.469% |
| Mesoblast Limited | -35.16 Million USD | 100.187% |
| Marizyme, Inc. | 457.7 Thousand USD | 85.64% |
| Genus plc | 178.7 Million USD | 99.963% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| Pharming Group N.V. | 220.1 Million USD | 99.97% |
| Therapeutic Solutions International, Inc. | 62.22 Thousand USD | -5.628% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | 83.975% |
| Nymox Pharmaceutical Corporation | -11 Thousand USD | 697.527% |
| ContraFect Corporation | -154 Thousand USD | 142.681% |
| PsyBio Therapeutics Corp. | -50 Thousand USD | 231.456% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | 14.373% |
| IMV Inc. | -962.29 Thousand USD | 106.83% |
| AXIM Biotechnologies, Inc. | -387.5 Thousand USD | 116.962% |
| MultiCell Technologies, Inc. | 49.32 USD | -133168.451% |
| ONE Bio Corp. | 20.12 Million USD | 99.673% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 40.26 Million USD | 99.837% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 48.9 Thousand USD | -34.413% |
| Q BioMed Inc. | -8988.00 USD | 831.286% |
| Emmaus Life Sciences, Inc. | 28.25 Million USD | 99.767% |
| Mosaic ImmunoEngineering Inc. | - USD | -Infinity% |
| Biomind Labs Inc. | -15.42 Thousand USD | 526.141% |
| American Oriental Bioengineering, Inc. | 44.35 Million USD | 99.852% |
| Provectus Biopharmaceuticals, Inc. | -1.14 Million USD | 105.758% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | 6.103% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | -4952.00 USD | 1427.302% |
| Acro Biomedical Co., Ltd. | 140.5 Thousand USD | 53.219% |
| Curative Biotechnology, Inc. | -97.51 Thousand USD | 167.403% |
| GB Sciences, Inc. | -624.00 USD | 10633.333% |
| Alpha Cognition Inc. | -86.02 Thousand USD | 176.403% |
| HST Global, Inc. | - USD | -Infinity% |
| CSL Limited | 7.56 Billion USD | 99.999% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Halberd Corporation | -208.00 USD | 31700.0% |
| Enzolytics Inc. | 30.7 Thousand USD | -114.042% |
| Agentix Corp. | - USD | -Infinity% |
| Resverlogix Corp. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | 482.43 Thousand USD | 86.376% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.1 Billion USD | 99.994% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | -514.51 Thousand USD | 112.775% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | 89.354% |
| Zenith Capital Corp. | - USD | -Infinity% |
| Genscript Biotech Corporation | 409.55 Million USD | 99.984% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -8856.00 USD | 842.186% |
| WPD Pharmaceuticals Inc. | - USD | -Infinity% |
| Cotinga Pharmaceuticals Inc. | -83.84 Thousand USD | 178.389% |
| Kadimastem Ltd | -630.13 Thousand USD | 110.431% |
| Helix BioMedix, Inc. | 987.98 Thousand USD | 93.347% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 9.61 Million USD | 99.316% |
| BioStem Technologies, Inc. | 15.42 Million USD | 99.574% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | - USD | -Infinity% |
| LadRx Corporation | -11.83 Thousand USD | 655.37% |
| Cell Source, Inc. | - USD | -Infinity% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | 62.773% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | 62.773% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Affymax, Inc. | 1.35 Million USD | 95.157% |
| Itoco Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | - USD | -Infinity% |
| CytoDyn Inc. | -29 Thousand USD | 326.648% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 450.04 Thousand USD | 85.395% |
| SYBLEU INC | 11.69 Thousand USD | -461.97% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | -Infinity% |
| International Stem Cell Corporation | 4.6 Million USD | 98.574% |
| Bioxytran, Inc. | -8285.00 USD | 893.337% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | - USD | -Infinity% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | -373 Thousand USD | 117.621% |
| Neutra Corp. | 14.33 Thousand USD | -358.514% |
| Windtree Therapeutics, Inc. | -82 Thousand USD | 180.156% |
| PureTech Health plc | -1.6 Million USD | 104.1% |
| Coeptis Therapeutics, Inc. | -1 Million USD | 106.565% |
| IXICO plc | 3.27 Million USD | 97.99% |
| IntelGenx Technologies Corp. | -694 Thousand USD | 109.471% |
| Gelesis Holdings, Inc. | -1.79 Million USD | 103.67% |
| CSL Limited | 7.7 Billion USD | 99.999% |
| Cellectis S.A. | 18 Thousand USD | -265.156% |